European Penny Stocks To Watch In August 2025

The European markets have recently faced challenges, with key indices like the STOXX Europe 600 and major national indexes experiencing declines amid mixed economic signals and trade deal uncertainties. Despite these broader market fluctuations, opportunities can still be found in niche areas such as penny stocks. Although the term "penny stocks" might seem outdated, these smaller or newer companies can offer intriguing investment prospects for those willing to explore beyond the mainstream, particularly when they exhibit strong financial fundamentals.

Top 10 Penny Stocks In Europe

Click here to see the full list of 335 stocks from our European Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Arterra Bioscience (BIT:ARBS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Arterra Bioscience S.p.A. is a research-based biotech company focused on the development of various ingredients and natural solutions, with a market cap of €17.05 million.

Operations: The company's revenue is primarily derived from its Specialty Chemicals segment, which generated €4.17 million.

Market Cap: €17.05M

Arterra Bioscience, with a market cap of €17.05 million and revenue primarily from its Specialty Chemicals segment (€4.17 million), presents a mixed picture for investors. Its earnings have grown by 8.7% annually over the past five years, although recent growth of 24.2% did not outpace industry averages. The company maintains strong financial health with more cash than debt and short-term assets exceeding liabilities, but its dividend sustainability is questionable due to insufficient free cash flow coverage. Despite a low Price-To-Earnings ratio (12.8x) compared to the Italian market, its Return on Equity remains modest at 11.7%.

• Click here to discover the nuances of Arterra Bioscience with our detailed analytical financial health report.
• Explore historical data to track Arterra Bioscience's performance over time in our past results report.

Antares Vision (BIT:AV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Antares Vision S.p.A. specializes in producing, installing, and maintaining inspection systems for quality control, with a market cap of €336.88 million.

Operations: The company's revenue segment includes Industrial Automation & Controls, generating €207.66 million.

Market Cap: €336.88M

Antares Vision S.p.A., with a market cap of €336.88 million, operates in the Industrial Automation & Controls sector, generating €207.66 million in revenue. Despite being unprofitable and experiencing increased losses over the past five years, it maintains sufficient short-term assets to cover both its short and long-term liabilities. The company's net debt to equity ratio is high at 45.2%, yet it has a cash runway exceeding three years due to positive free cash flow, albeit shrinking annually by 17%. Earnings are forecasted to grow significantly at 92.17% per year, but management's lack of experience may pose challenges ahead.

• Dive into the specifics of Antares Vision here with our thorough balance sheet health report.
• Gain insights into Antares Vision's outlook and expected performance with our report on the company's earnings estimates.

Cyberoo (BIT:CYB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cyberoo S.p.A. offers managed and cyber security services in Italy, with a market cap of €72.14 million.

Operations: The company generates revenue through three primary segments: Cyber Security & Device Security (€17.97 million), Managed Services (€4.70 million), and Digital Transformation (€0.16 million).

Market Cap: €72.14M

Cyberoo S.p.A., with a market cap of €72.14 million, generates revenue primarily from Cyber Security & Device Security (€17.97 million) and Managed Services (€4.70 million). The company benefits from experienced management (6.7 years average tenure) and board members (3.9 years average tenure). Despite a decline in net profit margins to 17.5%, earnings have grown significantly over the past five years at 51.1% per year, although recent growth has slowed to 10.4%. Cyberoo's debt is well covered by operating cash flow, and it holds more cash than total debt, indicating strong financial health amidst high share price volatility recently observed in Italian stocks.

• Take a closer look at Cyberoo's potential here in our financial health report.
• Explore Cyberoo's analyst forecasts in our growth report.

Summing It All Up

• Click this link to deep-dive into the 335 companies within our European Penny Stocks screener.
• Ready For A Different Approach? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com